Gilead Sciences (GILD)
Health Care · Biotechnology / Pharmaceutical · NASDAQ
A leading biopharmaceutical innovator specializing in life-saving HIV therapies and complex CAR T-cell cancer treatments.
What Gilead Sciences does
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. The company focuses primarily on HIV treatment and prevention, as well as cell therapy for oncology.
Themes: HIV treatment and prevention, oncology / cancer therapy, cell therapy, biopharmaceuticals
Fundamentals
- Price$147.10 as of 2026-10-08 close
- Market cap$182.4B as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+24.4% 2025-10-08 close $118.25 → 2026-10-08 close $147.10
- P/En/a negative earnings
- Net margin+28.9% FY2025, SEC XBRL
- ROE+37.6% FY2025, SEC XBRL
- Debt / equity2.22 as of 2026-09-03
- Revenue growth (YoY)+5.5% as of 2026-09-03
- Revenue CAGR (3y)+2.6% SEC XBRL
- Beta0.37 as of 2026-09-03
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +2.2%; 11-year non-decreasing per-share dividend streak (SEC XBRL).
How GILD compares in its sector
- net profit margintop 10% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 10% 417 covered Health Care peers, as of 2026-09-03
- return on equitytop 10% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 72 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, GILD's dividend was covered by reported results (earnings payout 47%, free-cash-flow payout 42%). This describes past coverage, not a forecast.
- Earnings payout47% dividends / net income
- Free-cash-flow payout42% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Gilead Sciences looks technically
Gilead Sciences (GILD) is trading 7.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 30 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 13 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 7.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +7.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $144.31 | $144.31 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $137.16 | $137.16 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 154.2. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 30 trading days ago — a "golden cross", a bullish long-term signal | 30 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 21.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30) | 50.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($142.60 to $154.20) — its "stochastic" reading is 39 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 38.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $157.27 | $157.27 |
|---|---|---|
| From the 52-week high | it is 6.5% below its 52-week high (its highest price of the past year) | -6.5% |
| Above the 52-week low | it is 34.1% above its 52-week low (its lowest price of the past year) | +34.1% |
| Below the 52-week high | it is 6.5% below its highest point of the past year | 6.5% |
| Since a 20-day breakout | it made a new 20-day high about 13 trading days ago | 13 sessions |
| Since a 55-day breakout | it made a new 55-day high about 13 trading days ago | 13 sessions |
| All-time high | its highest closing price on record is $157.27 (set on 2026-02-11) | $157.27 |
| Given back of the 52-week move | over the past year its closes ranged ($112.69 to $155.80), and it has given back roughly a quarter of its rise from last year’s low — 20% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $127.78 to $129.16. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 20.2% |
| From the all-time high | it is 6.5% below its all-time high | -6.5% |
| Nearest price level | it is trading 2.8% above a support level at $142.99 — a price it turned at five times since 2026-02-26, most recently on 2026-09-15. Since 2024-10-08 it has 12 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.8% |
| All-time low | its lowest closing price on record is $0.5313 (set on 1996-08-07) | $0.5313 |
| Above the all-time low | it is 27589.4% above its all-time low | +27,589% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 41st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.42 between its high and its low — about 2.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.42 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $142.87 and $153.92 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $142.87 – $148.40 – $153.92 |
| Typical daily range (% of price) | its price moves about 2.3% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.3% |
| Stretch from the 200-day average | it is trading 2.9 daily ranges above its 200-day average price (7.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.80× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 at essentially the same price it closed at the session before — no meaningful overnight gap | -0.1% |
|---|---|---|
| Gap filled | a 2.7% gap down opened on 2026-09-08 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it took 7 sessions to close | 15 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +1.99% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 0.7 percentage points (the stock gained 0.3% while the market gained 1.0%) | -0.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 4.5 percentage points (the stock gained 8.3% while the market gained 3.8%) | +4.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 12.5 percentage points (the stock gained 5.0% while the market gained 17.5%) | -12.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 9.4 percentage points (the stock gained 24.4% while the market gained 15.0%) | +9.4% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.0% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.5% of the share price. | +3.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $137.32 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +7.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% above the average price paid since it last reported on 2026-08-04 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $144.61 — a volume-weighted average of daily closes over 47 sessions, not a true tick-by-tick VWAP. | +1.7% |
Rising wedge, bearish — broke down · entry $149.65 · 66 sessions in
Price levels it has turned at before
GILD last closed at $147.10 on 2026-10-08. Since 2024-10-08 it has turned at 12 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $142.99 | Support | 2.8% below the last close | turned there five times · 2026-02-26 to 2026-09-15 |
| $153.38 | Resistance | 4.3% above the last close | turned there twice · 2026-09-02 to 2026-09-23 |
| $137.29 | Support | 6.7% below the last close | turned there five times · 2026-05-12 to 2026-08-05 |
| $128.12 | Support | 12.9% below the last close | turned there six times · 2025-11-20 to 2026-07-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $154.20.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 7 trading days, since 2026-09-30.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · lagging the market · Trading above the Ichimoku cloud · Completed Elliott five-wave sequences | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.68 mean, 1=Strong Buy…5=Strong Sell) — 26 analysts
- Mean price target$159.38 range $126.00 – $180.00; median $164.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for GILD
- Consensus EPS estimate$2.16 next reporting period, as of 2026-10-09
- Estimate change, 30 days+$0.01959 (+0.9%) from $2.14, on 2026-09-04, 35-day window
- Readings revised upward25% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Substantial revenue reliance on HIV products subject to market share loss or generic competition.","Manufacturing and supply chain complexity for personalized CAR T-cell therapies (Yescarta, Tecartus).","Regulatory risks related to FDA safety mandates, clinical trial outcomes, and pricing/reimbursement pressures."]
What changed in the latest 10-Q
AI-assisted comparison of GILD's 10-Q filed 2026-08-06 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- In the newer filing (2026-08-06): the introductory paragraph now references 'the three and six months ended June 30, 2026' instead of only 'the three months ended March 31, 2026'.
- Removed:
- In the older filing (2026-05-07): the introductory paragraph referenced 'the three months ended March 31, 2026', which is no longer present in the newer filing.
- Reworded:
- The newer filing changes the period reference from 'the three months ended March 31, 2026' to 'the three and six months ended June 30, 2026'.
- Notes:
- The newer MD&A text appears truncated at '(including the disclosures under Part II,' and may not represent the complete section.
Risk Factors
- Reworded:
- Newer filing (2026-08-06) states: "The use of engineered T cells as a potential cancer treatment is a relatively recent development... For example, the FDA has required a class-wide labeling change for all approved CAR T-cell therapies, including a Boxed Warning regarding the risk of T-cell malignancies following treatment with CAR T-cell therapy." Older filing (2026-05-07) states: "The use of engineered T cells as a potential cancer treatment is a recent development... For example, in January 2024, FDA instituted a class labeling change for all approved CAR T-cell therapies, including a 'boxed warning' about the possible risk of secondary T-cell malignancies in patients treated with CAR T-cell therapy."
- Newer filing (2026-08-06) ends with: "...fluctuations in purchasing patterns or" (followed by a page break), while older filing (2026-05-07) ends with: "...fluctuations in purchasing" (followed by a page break) — source text truncation differs.
- Notes:
- Both source texts are truncated at a page break and may continue in unreported sections.
- Page number at the truncation point differs: newer filing shows page 39, older filing shows page 32.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 26 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 6 sells ($3M) — 3 selling insiders
- Last 90 days · read to 2026-10-040 buys · 26 sells ($16M) — 5 selling insiders
- Last 180 days · read to 2026-10-040 buys · 44 sells ($27M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-01. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about GILD's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 13 matched disclosures for GILD from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding GILD as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 263,591,821
- Reported value $33,302,190,832
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about GILD's institutional holders → See what each manager we track holds →
Short interest (FINRA)
GILD had 18,304,875 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
GILD had 1.48% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.65 days to cover at the same settlement.
- Reported short interest (shares) 18,304,875
- Short interest (% of shares outstanding) 1.48%
- Prior settlement (shares) 23,007,029
- Reported change -20.44%
- Days to cover (reported) 3.65
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- GSK (GSK)
- Johnson & Johnson (JNJ)
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
- Merck & Co. (MRK)
- AstraZeneca (AZN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GILD vs…
Gilead Sciences is found in…
GILD ranks in…
Frequently asked questions
What does Gilead Sciences (GILD) do?
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. The company focuses primarily on HIV treatment and prevention, as well as cell therapy for oncology.
What sector is Gilead Sciences (GILD) in?
Gilead Sciences (GILD) is classified in the Health Care sector. Its industry is Biotechnology / Pharmaceutical. It trades on NASDAQ.
Does GILD pay a dividend?
Yes — Gilead Sciences (GILD) pays a dividend, with an indicated yield of about 2.19% and 11-year non-decreasing per-share dividend streak (SEC EDGAR XBRL) (market data, as of 2026-09-03). Informational only — not financial advice.
Who are Gilead Sciences's (GILD) competitors?
Notable peers of Gilead Sciences (GILD) include GSK, Johnson & Johnson, Novartis, Bristol Myers Squibb and Merck & Co.. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in GILD?
Yes — we hold 13 matched STOCK Act disclosures for GILD from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Gilead Sciences (GILD) overbought or oversold right now?
Gilead Sciences (GILD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 50, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GILD come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.